
Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.




Department of Clinical Effectiveness V8 Approved by the Executive Committee of the Medical Staff on 08/15/2023

Page 1 of 7

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.



Page 2 of 7

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

APPENDIX A: Antiemetic Medication Options for Prophylaxis

Drug	Dosage	Timing	Comments	
Anticholinergics Scopolamine Patch (Transderm Scop [®])	1.5 mg disc placed behind ear	At least 2 - 4 hours before surgery	 Caution in patients > 60 years old Patch may be applied the night prior to surgery If not discontinued prior to hospital discharge, patients should be instructed in the safe removal and disposal of the patch 	
Benzodiazepines Midazolam (Versed [®])	35 - 75 mcg/kg IV	May be given pre-operatively or intra-operatively		
Butyrophenones Droperidol (Inapsine [®]) ¹	0.625 mg IV	Most effective if given at the end of surgery	 Requires 2 – 3 hours of EKG monitoring Known risk² of TdP 	
Haloperidol (Haldol [®])	1 mg IV	Give at the end of surgery	 Alternative to droperidol Known risk² of TdP and precludes its use as a first-line agent 	
Corticosteroids Dexamethasone	4-8 mg IV	Give shortly after induction	Avoid in labile diabetic patients	
Dopamine Antagonist Amisulpride (Barhemsys [®])	5 mg IV	Give at the time of induction	 Less likely to cause adverse reactions such as extrapyramidal symptoms Conditional risk² of TdP 	

TdP = torsades de pointes

¹Availability varies based on supply

² The Arizona Center for Education and Research on Therapeutics (AZCERT)'s Adverse Drug Event Causality Analysis (ADECA) Risk Categories

• Known risk: Drugs in this category prolong the QT interval and are clearly associated with a risk of TdP, even when taken as recommended

• Possible risk: Drugs in this category can cause QT prolongation but currently lack compelling evidence for a risk of TdP when the drug is taken as recommended

• Conditional risk: Drugs in this category have evidence of TdP but only under certain conditions of their use (*e.g.*, excessive dose, in patients with conditions such as hypokalemia or when they are taken with interacting drugs) or by creating conditions that facilitate or induce TdP (*e.g.*, by inhibiting metabolism of a QT-prolonging drug or by causing an electrolyte disturbance that induces and/or facilitates TdP)

Continued on next page

Page 3 of 7

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

APPENDIX A: Antiemetic Medication Options for Prophylaxis - continued

Drug	Dosage	Timing	Comments	
Neurokinin-1 Receptor Antagonists Aprepitant (Emend [®])	40 mg PO	Give within 3 hours before the induction of anesthesia		
Phenothiazines Promethazine (Phenergan [®])	6.25 mg IV	Give shortly after induction	 6.25 mg dose may require a second dose after 15 minutes; may repeat up to 3 times for a maximum dose of 25 mg Should not be used in children ≤ 2 years old Possible risk¹ of TdP 	
Prochlorperazine (Compazine [®])	5 - 10 mg IV	Give at the end of surgery	Risk of QTc prolongation did not reach the level to be placed in any of the TdP risk categories ¹ ; however, other tertiary drug information references ² and the product information ³ indicate ECG abnormalities (Q and T wave distortions) at an undefined frequency	
Serotonin Antagonists Ondansetron (Zofran [®])	4 mg IV	Give at the end of surgery	Known risk ¹ of TdP	
Granisetron	0.35 - 3 mg IV	Give at the end of surgery	 For patients with history of delayed (post-discharge) post-operative nausea and vomiting Possible risk¹ of TdP 	

¹ The Arizona Center for Education and Research on Therapeutics (AZCERT)'s Adverse Drug Event Causality Analysis (ADECA) Risk Categories

• Known risk: Drugs in this category prolong the QT interval and are clearly associated with a risk of TdP, even when taken as recommended

• Possible risk: Drugs in this category can cause QT prolongation but currently lack compelling evidence for a risk of TdP when the drug is taken as recommended

• Conditional risk: Drugs in this category have evidence of TdP but only under certain conditions of their use (*e.g.*, excessive dose, in patients with conditions such as hypokalemia or when they are taken with interacting drugs) or by creating conditions that facilitate or induce TdP (*e.g.*, by inhibiting metabolism of a QT-prolonging drug or by causing an electrolyte disturbance that induces and/or facilitates TdP)

² See Lexicomp

³See prochlorperazine product information

Page 4 of 7

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

APPENDIX B: Antiemetic Medication Options for Treatment or Rescue

Drug	Dosage	Comments		
Serotonin Antagonists Ondansetron (Zofran [®])	First Line Agent 4 mg IV	Known risk ¹ of TdP	Notes: • When nausea and vomiting occur post-operatively, treatment should be administered with an antiemetic from a DIFFERENT pharmacologic class than	
Phenothiazines Promethazine (Phenergan [®])	Second Line Agents 6.25 mg IV	 6.25 mg dose may require a second dose after 15 minutes; may repeat up to 3 times for a maximum dose of 25 mg Possible risk¹ of TdP 		
Prochlorperazine (Compazine [®])	5 - 10 mg IV	Risk of QTc prolongation did not reach the level to be placed in any of the TdP risk categories ¹ ; however, other tertiary drug information references ² and the product information ³ indicate ECG abnormalities (Q and T wave distortions) at an undefined frequency	 But i Effect i plantacorogic class that the drug given for prophylaxis initially Re-dosing should only occur if ≥ 6 hours has elapsed since the last dose from that class was given 	
Butyrophenones Droperidol (Inapsine [®]) ⁴	Third Line Agents 0.625 mg IV	 Requires 2 - 3 hours of EKG monitoring Known risk¹ of TdP 		
Haloperidol (Haldol [®])	1 mg IV	 Known risk¹ of TdP and precludes its use as a first-line agent Alternative to droperidol 		
Prokinetic Metoclopramide (Reglan [®])	Rescue 10 mg IV	Conditional risk ¹ of TdP		
Dopamine Antagonist Amisulpride (Barhemsys [®])	Rescue 10 mg IV	 Less likely to cause adverse reactions such as extrapyramidal symptoms Conditional risk¹ of TdP 		

TdP = torsades de pointes

¹The Arizona Center for Education and Research on Therapeutics (AZCERT)'s Adverse Drug Event Causality Analysis (ADECA) Risk Categories

• Known risk: Drugs in this category prolong the QT interval and are clearly associated with a risk of TdP, even when taken as recommended

• Possible risk: Drugs in this category can cause QT prolongation but currently lack compelling evidence for a risk of TdP when the drug is taken as recommended

• Conditional risk: Drugs in this category have evidence of TdP but only under certain conditions of their use (*e.g.*, excessive dose, in patients with conditions such as hypokalemia or when they are taken with interacting drugs) or by creating conditions that facilitate or induce TdP (*e.g.*, by inhibiting metabolism of a QT-prolonging drug or by causing an electrolyte disturbance that induces and/or facilitates TdP)

²See Lexicomp

³See prochlorperazine product information

⁴Availability varies based on supply

Copyright 2023 The University of Texas MD Anderson Cancer Center

Page 5 of 7

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS

- Apfel, C. C., Kranke, P., Greim, C. A., & Roewer, N. (2001). What can be expected from risk scores for predicting postoperative nausea and vomiting? *British Journal of Anaesthesia*, 86(6), 822-827. https://doi.org/10.1093/bja/86.6.822
- Bolac, C. S., Wallace, A. H., Broadwater, G., Havrilesky, L. J., & Habib, A. S. (2013). The impact of postoperative nausea and vomiting prophylaxis with dexamethasone on postoperative wound complications in patients undergoing laparotomy for endometrial cancer. *Anesthesia & Analgesia, 116*(5), 1041-1047. https://doi.org/10.1213/ANE.0b013e318276cf58
- Diemunsch, P. (2008). Conference of experts--short text. Management of postoperative nausea and vomiting. French Society of Anesthesia and Resuscitation. *Annales Francaises d'Anesthesie et de Reanimation*, 27(10), 866-878. https://doi.org/10.1016/j.annfar.2008.09.004
- Eberhart, L. H., & Morin, A. M. (2011). Risk scores for predicting postoperative nausea and vomiting are clinically useful tools and should be used in every patient: Con "life is really simple, but we insist on making it complicated." *European Journal of Anaesthesiology*, *28*(3), 155-159. https://doi.org/10.1097/EJA.0b013e3283427f4f
- Gan, T. J., Belani, K. G., Bergese, S., Chung, F., Diemunsch, P., Habib, A. S., . . . Philip, B. K. (2020). Fourth consensus guidelines for the management of postoperative nausea and vomiting. *Anesthesia & Analgesia*, 131(2), 411-448. https://doi.org/10.1213/ANE.000000000004833
- Gan, T. J., Diemunsch, P., Habib, A. S., Kovac, A., Kranke, P., Meyer, T. A., . . . Tramer, M. R. (2014). Consensus guidelines for the management of postoperative nausea and vomiting. *Anesthesia & Analgesia, 118*(1), 85-113. https://doi.org/10.1213/ANE.0000000000000002
- Gan, T. J., Meyer, T. A., Apfel, C. C., Chung, F., Davis, P. J., Habib, A. S., . . . Watcha, M. (2007). Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. *Anesthesia & Analgesia*, *105*(6), 1615-1628. https://doi.org/10.1213/01.ane.0000295230.55439.f4
- Gómez-Arnau, J., Aguilar, J., Bovaira, P., Bustos, F., De Andrés, J., de La Pinta, J., . . . Torres, L. (2010). Postoperative nausea and vomiting and opioid-induced nausea and vomiting: Guidelines for prevention and treatment. *Revista Espanola de Anestesiologia y Reanimacion*, 57(8), 508-524. https://doi.org/10.1016/S0034-9356(10)70711-8
- Kranke, P. (2011). Effective management of postoperative nausea and vomiting: Let us practice what we preach! *European Journal of Anaesthesiology*, 28(3), 152-154. https://doi.org/10.1097/EJA.0b013e3283435e51
- Pierre, S. (2011). Risk scores for predicting postoperative nausea and vomiting are clinically useful tools and should be used in every patient: Pro "Don't throw the baby out with the bathwater." *European Journal of Anaesthesiology*, 28(3), 160-163. https://doi.org/10.1097/EJA.0b013e328342fd86
- Rüsch, D., Eberhart, L. H. J., Wallenborn, J., & Kranke, P. (2010). Nausea and vomiting after surgery under general anesthesia: An evidence-based review concerning risk assessment, prevention, and treatment. *Deutsches Ärzteblatt International*, 107(42), 733-741. https://doi.org/10.3238/arztebl.2010.0733
- Woosley, R.L., Heise, C.W., Gallo, T., Woosley, D. and Romero, K.A., www.CredibleMeds.org, *QTdrugs List*, [May 24, 2023], AZCERT, Inc. 1457 E. Desert Garden Dr., Tucson, AZ 85718

Page 6 of 7

Making Cancer History®

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice consensus statement is based on majority expert opinion of the Nausea and Vomiting experts at the University of Texas MD Anderson Cancer Center for the patient population. These experts included:

Core Development Team Leads

Sydney Pham, MD (Anesthesiology & Peri-operative Medicine)

Workgroup Members

Katherine Cain, PharmD (Pharmacy Clinical Programs) Wendy Garcia, BS[•] Jacob Hall, PharmD (Pharmacy Clinical Programs) Thoa Kazantsev, MSN, RN, OCN[•] Claire Marten, PharmD (Pharmacy Clinical Programs) Laura Michaud, PharmD, BCOP, FASHP, CMQ (Pharmacy) Sasha Ramirez, BS, RN (Post Anesthesia Care Unit) Joseph Ruiz, MD (Anesthesiology & Peri-operative Medicine)

* Clinical Effectiveness Development Team

Page 7 of 7